To Get Full Access :

NCE-1 Intelligence & Market Opportunity

Hovilpri

Pritelivir
Oral Tablet

Hovilpri (pritelivir) is an FDA-approved oral antiviral medicine used to treat hard-to-treat herpes simplex virus (HSV) infections in adults with weakened immune systems. It is prescribed when standard antiviral medicines, such as acyclovir, valacyclovir, or famciclovir, do not work. These infections can cause sores on the skin and moist surfaces of the body, including the lips, eyes, and genitals.

Hovilpri works differently from older antiviral medicines. It blocks two proteins, called helicase and primase, that the virus needs to multiply. This makes it effective against some HSV strains that no longer respond to existing treatments. Developed by AiCuris Anti-infective Cures AG, now part of Asahi Kasei Therapeutics, Hovilpri is the first FDA-approved HSV treatment with this new way of working in nearly 30 years.

Approval Date
09-Oct-26
NCE-1 Date
09-Oct-30
NCE Date
09-Oct-31
Commercial snapshot

Market performance & projections

Revenue ($M)
NA
CAGR (%)
NA
Projected sales, 2026–2032 ($M)
Analyst projection, $M per year
2026
NA
2027
NA
2028
NA
2029
NA
2030
NA
2031
NA
2032
NA
Molecule profile

Details & specifications

Molecule
Pritelivir
Innovator
AICURIS ANTI-INFECTIVE CURES AG
Dosage Form
Oral Tablet
Strength
EQ 100MG BASE
Therapeutic Category
Usage
To treat adults with weakened immune systems who have mucocutaneous lesions caused by herpes simplex virus infection and have not responded to other therapies
Good to know

Frequently asked questions

Ready to act on this opportunity?

Talk to Spring Bio Solution about sourcing, licensing, and filing support for this molecule.

Why Spring Bio Solution

Supported 1000+ clinical trials globally

Provides services across regulatory, legal & clinical research

Unmatched intelligence on batches, expiry, spacing, and historical data from innovators

Integrated CRO services as part of our offerings

Insights on global pricing for smarter clinical trial supply decisions

Global sourcing capability across US, EU, South Africa, Canada, Japan, Australia, New Zealand, Southeast Asia, and other key markets

What is Hovilpri used for?
How does Hovilpri work?
What were the results of Hovilpri’s Phase 3 clinical trial?
How is Hovilpri taken?
Hovilpri is used to treat hard-to-treat herpes simplex virus (HSV) infections in adults with weakened immune systems when standard antiviral medicines do not work.
It blocks two proteins, helicase and primase, that the virus needs to multiply. This helps stop the virus from spreading.
In the PRIOH-1 trial, around 63% of patients taking Hovilpri achieved complete lesion healing within 28 days, compared with 34% receiving other treatments.
Hovilpri comes as a 100 mg oral tablet taken by mouth.

Login With

For full access Sign-up / Sign-in using below Methods:

By continuing, you agree to our Terms & Conditions and Privacy Policy. You can review them anytime.

Are you sure want to logout from NCE Grid?